Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of “Moderate Buy” by Analysts

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $14.94.

Several equities analysts have issued reports on TERN shares. JMP Securities cut their target price on Terns Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. UBS Group cut their target price on Terns Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, March 27th. HC Wainwright reiterated a “neutral” rating and issued a $5.50 target price on shares of Terns Pharmaceuticals in a research note on Friday, March 15th. Finally, BMO Capital Markets lifted their target price on Terns Pharmaceuticals from $18.00 to $19.00 and gave the company an “outperform” rating in a research note on Friday, March 15th.

Insider Activity at Terns Pharmaceuticals

In related news, major shareholder Vivo Opportunity, Llc sold 181,117 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $6.99, for a total value of $1,266,007.83. Following the sale, the insider now owns 275,772 shares in the company, valued at $1,927,646.28. The sale was disclosed in a legal filing with the SEC, which is available through this link. 17.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. PEAK6 Investments LLC raised its stake in shares of Terns Pharmaceuticals by 35.5% during the 3rd quarter. PEAK6 Investments LLC now owns 19,097 shares of the company’s stock worth $96,000 after buying an additional 5,000 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Terns Pharmaceuticals by 358.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,147 shares of the company’s stock valued at $46,000 after purchasing an additional 5,587 shares during the last quarter. AJOVista LLC acquired a new position in Terns Pharmaceuticals in the 4th quarter valued at $58,000. Simplicity Solutions LLC acquired a new position in Terns Pharmaceuticals in the 4th quarter valued at $68,000. Finally, Bleakley Financial Group LLC acquired a new position in Terns Pharmaceuticals in the 4th quarter valued at $68,000. 98.26% of the stock is owned by institutional investors and hedge funds.

Terns Pharmaceuticals Price Performance

TERN stock opened at $4.75 on Thursday. The business has a 50-day moving average price of $6.51 and a 200 day moving average price of $5.86. The company has a market capitalization of $307.09 million, a P/E ratio of -3.74 and a beta of -0.63. Terns Pharmaceuticals has a 1-year low of $3.26 and a 1-year high of $13.51.

Terns Pharmaceuticals (NASDAQ:TERN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.29) earnings per share for the quarter, meeting the consensus estimate of ($0.29). On average, analysts anticipate that Terns Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.